The University of Colorado Cancer Center (UCCC) is the only NCI-designated comprehensive Cancer Center in Colorado serving a primary catchment area of Colorado and Wyoming with a population of ~5.5M. During the past five years, peer-reviewed cancer-related funding reached $102M and 3,181 publications (35% collaborative) were produced. Outpatient visits and clinically active faculty are growing, which will translate into a ranked increase in patient accruals to clinical trials. UCCC is an NCI-recognized consortium encompassing Univ. of Colorado Boulder, Colorado State University, National Jewish Health, Univ. of Colorado Hospital (UCH), the Colorado Children's Hospital, Denver Health System, Kaiser Permanente of Colorado and the Denver Veterans Administration Medical Center. We also have a growing number of outreach clinics staffed directly by our faculty including Montrose Hospital in Montrose, Valley View Hospital in Glenwood Springs, and Vail Valley Medical Center in Edwards. Our affiliates (CGOPs) include St. Mary's in Grand Junction. UCH has constructed a new outpatient tower for oncology care (opened May 2012), and is nearing completion of a new inpatient tower (March 2013). UCH has merged with our former affiliates, Poudre Valley Medical Center (PVMH) in Ft. Collins and Memorial Hospital (MH) in Colorado Springs, under the unified University of Colorado Health Systems. The cancer components of these two hospital systems will formally join the UCCC consortium later this year. The LAPS U10-funded membership in the NCTN and in SWOG and NRG fulfills many of the goals of our Cancer Center by providing broad access to innovative Phases II and III treatment and chemoprevention trials to the citizens of Colorado. This grant provides partial support for the monitoring and oversight to run clinical trials at the main institutions. Our faculties have provided strong administrative and scientific leadership, throughout the NCTN, by serving or chairing SWOG and RTOG committees, serving as PIs for Phases ll/lll SWOG, GOG, ACOSOG, RTOG, and NSABP group trials including PLCO, PCPT, SELECT and NLST/ACRIN. Clinical trials represent the state-of-the-art in cancer treatment and prevention and should be broadly available and offered to the citizens of Colorado.
As the only NCI-designated Cancer Center in the State of Colorado, the UCCC innovates in the development of more effective approaches to prevention, diagnosis, and therapy of cancer. Clinical trials, especially Phase III studies, drive progress and establish new standards of care (SOC). This grant provides essential resources to support these clinical trials to our Cancer Center and to multiple sites around the Rocky Mountain region. Access to clinical trials is crucial for excellence in health care.
|Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888|
|West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92|
|Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504|
|Cheng, Heather H; Plets, Melissa; Li, Hongli et al. (2018) Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer. Prostate 78:121-127|
|Weidhaas, Joanne B; Harris, Jonathan; Schaue, Dörthe et al. (2017) The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 3:483-491|
|Coleman, Robert L; Brady, Mark F; Herzog, Thomas J et al. (2017) Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18:779-791|
|Platz, Elizabeth A; Kulac, Ibrahim; Barber, John R et al. (2017) A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts. Cancer Epidemiol Biomarkers Prev 26:1549-1557|
|Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40|
|Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952|
|Creasman, William T; Ali, Shamshad; Mutch, David G et al. (2017) Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol 145:519-525|
Showing the most recent 10 out of 61 publications